文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

脂蛋白(a)与心血管疾病黑人和白人成年人冠心病和缺血性卒事件的风险。

Lipoprotein(a) and the Risk for Coronary Heart Disease and Ischemic Stroke Events Among Black and White Adults With Cardiovascular Disease.

机构信息

Department of Epidemiology University of Alabama at Birmingham AL.

Division of Cardiovascular Disease Department of Medicine University of Alabama at Birmingham AL.

出版信息

J Am Heart Assoc. 2022 Jun 7;11(11):e025397. doi: 10.1161/JAHA.121.025397. Epub 2022 May 27.


DOI:10.1161/JAHA.121.025397
PMID:35621195
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9238745/
Abstract

Background It is unclear whether lipoprotein(a) is associated with coronary heart disease (CHD) and ischemic stroke events in White and Black adults with atherosclerotic cardiovascular disease (ASCVD). Methods and Results We conducted a case-cohort analysis, including Black and White REGARDS (Reasons for Geographic and Racial Differences in Stroke) study participants ≥45 years of age with prevalent ASCVD (ie, CHD or stroke) at baseline between 2003 and 2007. Baseline lipoprotein(a) molar concentration was measured in participants with ASCVD who experienced a CHD event by December 2017 (n=1166) or an ischemic stroke by September 2019 (n=492) and in a random subcohort of participants with prevalent ASCVD (n=1948). The hazard ratio (HR) for CHD events per 1 SD (1.5 units) higher log-transformed lipoprotein(a) was 1.26 (95% CI, 1.02-1.56) among Black participants and 1.16 (95% CI, 1.02-1.31) among White participants ( value comparing HRs, 0.485). The HR for CHD events per 1 SD higher log-lipoprotein(a) within subgroups with hs-CRP (high-sensitivity C-reactive protein) ≥2 and <2 mg/L was 1.31 (95% CI, 0.99-1.73) and 1.23 (95% CI, 0.85-1.80), respectively ( value comparing HRs, 0.836), among Black participants, and 1.07 (95% CI, 0.91-1.27) and 1.36 (95% CI, 1.10-1.70), respectively ( value comparing HRs, 0.088), among White participants. There was no evidence that the association between lipoprotein(a) and CHD events differed by statin use. There was no evidence of an association between lipoprotein(a) and ischemic stroke events among Black or White participants. Conclusions Higher lipoprotein(a) levels were associated with an increased risk for CHD events in Black and White adults with ASCVD.

摘要

背景:脂蛋白(a) 是否与白人和黑人患有动脉粥样硬化性心血管疾病 (ASCVD) 的成年人的冠心病 (CHD) 和缺血性卒中事件相关尚不清楚。

方法和结果:我们进行了病例-队列分析,纳入了 2003 年至 2007 年期间基线时患有 ASCVD(即 CHD 或卒中)的≥45 岁的黑人及白人 REGARDS(地理和种族差异导致的卒中原因)研究参与者。在 2017 年 12 月之前发生 CHD 事件的 ASCVD 患者(n=1166)或 2019 年 9 月之前发生缺血性卒中的患者(n=492)和随机选择的具有 ASCVD 的患者亚组(n=1948)中,测量了基线脂蛋白(a)摩尔浓度。黑人参与者中,每增加 1 个标准差 (1.5 个单位) 的脂蛋白(a),CHD 事件的风险比 (HR) 为 1.26 (95%CI,1.02-1.56),白人参与者中为 1.16 (95%CI,1.02-1.31)(比较 HR 值的 值,0.485)。在 hs-CRP(高敏 C 反应蛋白)≥2 和 <2 mg/L 的亚组内,脂蛋白(a)每增加 1 个标准差的 HR 分别为 1.31 (95%CI,0.99-1.73) 和 1.23 (95%CI,0.85-1.80)(比较 HR 值的 值,0.836),黑人参与者;分别为 1.07 (95%CI,0.91-1.27) 和 1.36 (95%CI,1.10-1.70)(比较 HR 值的 值,0.088),白人参与者。没有证据表明脂蛋白(a)与 CHD 事件之间的关联因他汀类药物的使用而有所不同。没有证据表明脂蛋白(a)与黑人或白人参与者的缺血性卒中事件之间存在关联。

结论:在患有 ASCVD 的黑人和白人成年人中,较高的脂蛋白(a)水平与 CHD 事件风险增加相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/104c/9238745/a9bc65599b5b/JAH3-11-e025397-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/104c/9238745/6b80f74afb5a/JAH3-11-e025397-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/104c/9238745/f4509bd904a4/JAH3-11-e025397-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/104c/9238745/496820479a60/JAH3-11-e025397-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/104c/9238745/8f8d30fd8aaa/JAH3-11-e025397-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/104c/9238745/a9bc65599b5b/JAH3-11-e025397-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/104c/9238745/6b80f74afb5a/JAH3-11-e025397-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/104c/9238745/f4509bd904a4/JAH3-11-e025397-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/104c/9238745/496820479a60/JAH3-11-e025397-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/104c/9238745/8f8d30fd8aaa/JAH3-11-e025397-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/104c/9238745/a9bc65599b5b/JAH3-11-e025397-g005.jpg

相似文献

[1]
Lipoprotein(a) and the Risk for Coronary Heart Disease and Ischemic Stroke Events Among Black and White Adults With Cardiovascular Disease.

J Am Heart Assoc. 2022-6-7

[2]
Incident CHD and ischemic stroke associated with lipoprotein(a) by levels of Factor VIII and inflammation.

J Clin Lipidol. 2023

[3]
Cardiovascular Disease Risk Assessment Using Traditional Risk Factors and Polygenic Risk Scores in the Million Veteran Program.

JAMA Cardiol. 2023-6-1

[4]
Coronary heart disease and ischemic stroke polygenic risk scores and atherosclerotic cardiovascular disease in a diverse, population-based cohort study.

PLoS One. 2023

[5]
Lipoprotein(a), C-Reactive Protein, and Cardiovascular Risk in Primary and Secondary Prevention Populations.

JAMA Cardiol. 2024-4-1

[6]
Soluble CD14, Ischemic Stroke, and Coronary Heart Disease Risk in a Prospective Study: The REGARDS Cohort.

J Am Heart Assoc. 2020-3-17

[7]
Assessment of Trends in Statin Therapy for Secondary Prevention of Atherosclerotic Cardiovascular Disease in US Adults From 2007 to 2016.

JAMA Netw Open. 2020-11-2

[8]
Association of Coronary Artery Calcium Score vs Age With Cardiovascular Risk in Older Adults: An Analysis of Pooled Population-Based Studies.

JAMA Cardiol. 2017-9-1

[9]
Associations of coagulation factors IX and XI levels with incident coronary heart disease and ischemic stroke: the REGARDS study.

J Thromb Haemost. 2017-6

[10]
Physical Activity, Parental History of Premature Coronary Heart Disease, and Incident Atherosclerotic Cardiovascular Disease in the Atherosclerosis Risk in Communities (ARIC) Study.

J Am Heart Assoc. 2016-8-30

引用本文的文献

[1]
Lipoprotein(a) Concentration and Cardiovascular Disease in a Group of Patients With Familial Hypercholesterolemia-A Lipid Clinic Experience.

Clin Cardiol. 2025-5

[2]
Sex Differences in the Association Between Lipoprotein(a) and Cardiovascular Outcomes: The MGB Lp(a) Registry.

J Am Heart Assoc. 2025-5-6

[3]
Rethinking cardiovascular risk: The emerging role of lipoprotein(a) screening.

Am J Prev Cardiol. 2025-2-14

[4]
Association of Lipoprotein(a) With Major Adverse Cardiovascular Events Across hs-CRP: A Systematic Review and Meta-Analysis.

JACC Adv. 2024-11-19

[5]
Lipoprotein(a) and risk-weighted apolipoprotein B: a novel metric for atherogenic risk.

Lipids Health Dis. 2024-9-27

[6]
Lipoprotein(a) and the Risk for Recurrent Ischemic Stroke Events.

JACC Adv. 2023-8-21

[7]
Genetics and Pathophysiological Mechanisms of Lipoprotein(a)-Associated Cardiovascular Risk.

J Am Heart Assoc. 2024-6-18

[8]
Synergistic effect of lipoprotein(a) and high-sensitivity C-reactive protein on the risk of all-cause and cardiovascular death in patients with acute myocardial infarction: a large prospective cohort study.

Front Endocrinol (Lausanne). 2024

[9]
Lipoprotein(a) Testing Trends in a Large Academic Health System in the United States.

J Am Heart Assoc. 2023-9-19

[10]
Lipoprotein(a) and the Risk for Recurrent Atherosclerotic Cardiovascular Events Among Adults With CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study.

Kidney Med. 2023-5-5

本文引用的文献

[1]
Association of Lipoprotein(a) With Recurrent Ischemic Events Following Percutaneous Coronary Intervention.

JACC Cardiovasc Interv. 2021-9-27

[2]
High-Sensitivity C-Reactive Protein Modifies the Cardiovascular Risk of Lipoprotein(a): Multi-Ethnic Study of Atherosclerosis.

J Am Coll Cardiol. 2021-9-14

[3]
Lipoprotein(a) and cardiovascular disease: prediction, attributable risk fraction, and estimating benefits from novel interventions.

Eur J Prev Cardiol. 2022-2-9

[4]
Age-Related Trajectories of Cardiovascular Risk and Use of Aspirin and Statin Among U.S. Adults Aged 50 or Older, 2011-2018.

J Am Geriatr Soc. 2021-5

[5]
Relation of First and Total Recurrent Atherosclerotic Cardiovascular Disease Events to Increased Lipoprotein(a) Levels Among Statin Treated Adults With Cardiovascular Disease.

Am J Cardiol. 2021-4-15

[6]
Lp(a) (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease: New Insights From a Large National Biobank.

Arterioscler Thromb Vasc Biol. 2021-1

[7]
Effect of C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients With High-Risk Vascular Disease: A Prespecified Secondary Analysis of the ACCELERATE Trial.

JAMA Cardiol. 2020-10-1

[8]
Impact of lipoprotein(a) on long-term outcomes after percutaneous coronary intervention in patients with reduced low-density lipoprotein cholesterol.

Rev Cardiovasc Med. 2020-3-30

[9]
A New Equation for Calculation of Low-Density Lipoprotein Cholesterol in Patients With Normolipidemia and/or Hypertriglyceridemia.

JAMA Cardiol. 2020-5-1

[10]
Ischemic Event Rates in Very-High-Risk Adults.

J Am Coll Cardiol. 2019-11-19

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索